Financhill
Buy
61

BKR Quote, Financials, Valuation and Earnings

Last price:
$44.61
Seasonality move :
8.38%
Day range:
$43.37 - $44.26
52-week range:
$30.93 - $49.40
Dividend yield:
1.97%
P/E ratio:
14.66x
P/S ratio:
1.57x
P/B ratio:
2.56x
Volume:
5M
Avg. volume:
7.2M
1-year change:
34.92%
Market cap:
$43.3B
Revenue:
$27.8B
EPS (TTM):
$2.98

BKR Analysts' Consensus Rating

The 19 analysts providing 12-month price projections for Baker Hughes shares anticipate an average target of $51.43, ranging from a low estimate of $40.00 to a high estimate of $58.00. This average target implies a growth of 17.68% compared to the current stock price of $43.70.

Consensus Price Target

$51.43

Highest Price Target

$58.00

Lowest Price Target

$40.00

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Analyst Ratings

6M Ago 1M Ago Current
Buy 15 14 13

Hold 4 6 6

Sell 0 0 0
Consensus Buy Buy Buy

BKR Recommendation Trends

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Alphabet Stock No Longer a Good Bet?
Is Alphabet Stock No Longer a Good Bet?

Alphabet tripled its price per share over the past 5…

Pepsi Vs Coke Stock: Which Is Best?
Pepsi Vs Coke Stock: Which Is Best?

Coca-Cola (NYSE:KO) and PepsiCo (NYSE:PEP) are two of the largest…

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Buy
52
RGC alert for Mar 19

Regencell Bioscience Holdings [RGC] is down 0.66% over the past day.

Sell
49
SRPT alert for Mar 19

Sarepta Therapeutics [SRPT] is up 8.72% over the past day.

Sell
46
CVNA alert for Mar 19

Carvana [CVNA] is up 5.74% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock